Read the current Defeat Diabetes® E-Lerts™ Newsletter

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

 
 
 
     
Rewarding for
you and us

Defeat Diabetes Foundation
    
      
       
Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300

Madeira Beach, FL 33708
  

Old Cholesterol Remedy Makes a Comeback

Posted: Friday, February 02, 2007

Studies show that adding niacin to a statin can raise HDL’s as much as 35% and reduce triglycerides by 50% and reduce the risk of heart attack or stroke by 70 percent.

In its therapeutic form, nicotinic acid, niacin can increase HDL as much as 35 percent when taken in high doses, usually about 2,000 milligrams per day. It also lowers LDL, though not as sharply as statins do, and it has been shown to reduce serum levels of artery-clogging triglycerides as much as 50 percent. Its principal side effect is an irritating flush caused by the vitamin’s dilation of blood vessels.

Despite its effectiveness, niacin has been the ugly duckling of heart medications, an old remedy that few scientists cared to examine. But that seems likely to change.

“There’s a great unfilled need for something that raises HDL,” said Dr. Steven E. Nissen, a cardiologist at the Cleveland Clinic and president of the American College of Cardiology. “Right now, in the wake of the failure of torcetrapib, niacin is really it. Nothing else available is that effective.”

In 1975, long before statins, a landmark study of 8,341 men who had suffered heart attacks found that niacin was the only treatment among five tested that prevented second heart attacks. Compared with men on placebos, those on niacin had a 26 percent reduction in heart attacks and a 27 percent reduction in strokes. Fifteen years later, the mortality rate among the men on niacin was 11 percent lower than among those who had received placebos.

Dr. B. Greg Brown, professor of medicine at the University of Washington in Seattle stated that, . “Here you have a drug that was about as effective as the early statins, and it just never caught on.” “It’s a mystery to me. But if you’re a drug company, I guess you can’t make money on a vitamin.”

 
By and large, research was focused on lowering LDL, and the statins proved to be remarkably effective. The drugs can slow the progress of cardiovascular disease, reducing the risk of heart attack or other adverse outcomes by 25 percent to 35 percent.
But recent studies suggest that the addition of an HDL booster like niacin may afford still greater protection.

After analyzing data from more than 83,000 heart patients who participated in 23 different clinical trials, researchers at the University of Washington calculated this month that a regimen that increased HDL by 30 percent and lowered LDL by 40 percent in the average patient would reduce the risk of heart attack or stroke by 70 percent. That is far more than can be achieved by reducing LDL alone.

Other small studies have produced similarly encouraging results, but some experts caution that the data on increased HDL and heart disease are preliminary.

Researchers at 72 sites in the United States and Canada are recruiting 3,300 heart patients for a study, led by Dr. Brown, comparing those who take niacin and a statin with those who take only a statin. This large head-on comparison should answer many questions about the benefits of combination therapy.

Many cardiologists see no reason to wait for the results. But niacin can be a bitter pill; in rare instances, the vitamin can cause liver damage and can impair the body’s use of glucose. High doses should be taken only under a doctor’s supervision.

A more frequent side effect is flushing. It becomes less pronounced with time, and often it can be avoided by taking the pills before bed with a bit of food. Doctors also recommend starting with small doses and working up to larger ones.

Extended-release formulations of the vitamin, taken once daily, are now available by prescription, and in many patients they produce fewer side effects. And a new Merck drug to counteract niacin-induced flushing is being tested in Britain. If it works, the company plans to bundle the drug with its own extended-release niacin and with Zocor, its popular statin.

“If it means preventing a heart attack, maybe it is better to put up with flushing than to wait for the next blockbuster.”

Source: Diabetes In Control

 
 
 
 
 
Join us on Facebook
 
 
 
 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.  
 
 

Send your unopened, unexpired test strips to:


Defeat Diabetes Foundation
150 153rd Ave, Suite 300
Madeira Beach, FL 33708

 

DDF advertisement
 

 Friendly Banner
 


Friendly Banner
 
 
 
Analyze nutrition content by portion
DDF advertisement